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Background
Human African trypanosomiasis (HAT) is caused by
Trypanosoma brucei rhodesiense or T.b. gambiense. Infection
with either parasite is fatal if untreated. The disease has 2
clinical stages, the early-stage where the parasites prolifer-
ate in the blood and lymph and the CNS-stage where the
parasites establish within the CNS. The only effective drug
for treatment of both forms of CNS-stage trypanosomiasis
is melarsoprol. Its use can cause the development of a
post-treatment reactive encephalopathy (PTRE) character-
ised by a severe meningoencephalitis with infiltration of
lymphocytes, macrophages and plasma cells. Astrocyte
and microglial activation are also apparent. Various
hypotheses exist regarding the pathogenesis of the PTRE.
Recent evidence indicates that the balance of cytokines
within the CNS may play a role in regulating the develop-
ment of the PTRE and that IL-10 helps to protect the CNS
from inflammatory pathology following early CNS inva-
sion. This study investigates the therapeutic potential of
IL-10 in a murine model of CNS-stage HAT.
Methods
Two groups of CD-1 mice were infected with 2 × 104 T.b.
brucei (GVR35/C1.8) parasites. One group was given 4 ug
of IL-10 daily by intraperitoneal injection for 14-days
beginning on day 17 post-infection. Both groups of mice
were treated with diminazene aceturate on day 24 post-
infection to precipitate a severe meningoencephalitis. The
animals were killed on day 31 post-infection and the
brain removed for histological evaluation using a neu-
ropathological grading scale. Control groups, consisting
of uninfected animals treated in an identical manner to
the experimental animals, were run in parallel with the
infected mice. Throughout the regimen all animals were
assessed clinically using a visual assessment scale.
Results
We have observed that both infected groups exhibit a sig-
nificantly (p = 0.0285, p = 0.0009) worse clinical picture
than uninfected mice [(mean ± SE) 0.00 ± 0.00] irrespec-
tive of IL-10 administration. No clinical difference (p =
0.6486) was apparent between infected animals given IL-
10 (1.659 ± 0.396) and those not given IL-10 (1.205 ±
0.319). However, neuropathological grading demon-
strates that IL-10 administration following infection sig-
nificantly (p = 0.0229) reduces (3.125 ± 0.248) the
severity of the CNS inflammation compared to animals
that did not receive IL-10 (3.875 ± 0.125). Infected groups
of mice had significantly (p < 0.0001) higher neuropatho-
logical scores than uninfected controls (0.00 ± 0.00).
Conclusion
The results of this study highlight IL-10, as a potential
adjunct to chemotherapy, through inhibiting the develop-
ment of the PTRE.
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